Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab
Source: Onc Live, May 2022
Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.